Ivarmacitinib for palmoplantar pustulosis (open-label, single-arm treatment)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-arm, open-label trial at Xijing Hospital testing oral ivarmacitinib in adults with clinically confirmed palmoplantar pustulosis who have failed or are intolerant of prior systemic therapy. Participants who meet lab and safety criteria will receive ivarmacitinib and be followed for changes in skin pustules, redness, symptom severity, and any joint symptoms, along with routine safety labs. The trial excludes patients with significant cytopenias, abnormal liver or kidney tests, or active infections such as tuberculosis or hepatitis. Safety monitoring and symptom measures will be used to characterize both benefit and potential harms of the drug.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* ≥18 years old; clinically/pathologically confirmed PPP; failure/intolerance to ≥1 conventional systemic therapy (12-24 weeks of standard dosing); physician-judged suitability for ivarmacitinib; signed informed consent.

Exclusion Criteria:

* Lymphocyte count \<0.5×10⁹/L, neutrophils \<1×10⁹/L, platelets \<100×10⁹/L, or hemoglobin \<80g/L; serum creatinine \>132.6μmol/L, AST/ALT \>2×ULN, or total bilirubin \>2.0mg/dL; active infections (tuberculosis, hepatitis B/C, systemic candidiasis); other conditions hindering participation or data interpretation.

Where it's running

• Xijing hospital
  Xi'an, Shaanxi, China Recruiting

Study contacts

• Study coordinator: Gang Wang, Phd
• Email: xjwgang@fmmu.edu.cn
• Phone: 15102994796

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ivarmacitinib with Camrelizumab and Fruquintinib in advanced colorectal cancer after prior therapies

  This trial tests whether combining ivarmacitinib with camrelizumab and fruquintinib can help patients with metastatic colorectal cancer who have progressed after multiple treatments.

  Recruiting Phase 2 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT07896096

• Low-dose ATG/PTCy plus ivarmacitinib to prevent acute GVHD after haploidentical PBSC transplant from parous female donors

  This tests whether adding the oral JAK1 inhibitor ivarmacitinib to low-dose ATG and post‑transplant cyclophosphamide can prevent acute GVHD in adults receiving haploidentical peripheral blood stem cell transplants from parous female donors.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07570745

• Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

  This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT07505186

• Xeligekimab for moderate-to-severe palmoplantar pustulosis

  This study will test whether Xeligekimab injections can reduce symptoms and improve quality of life in adults with moderate to severe palmoplantar pustulosis.

  Recruiting Phase 4 First Hospital of China Medical University · Shenyang · NCT07503652

• Picankibart for palmoplantar pustulosis

  This open-label study will test whether picankibart helps adults aged 18-65 with palmoplantar pustulosis who haven't improved after at least one standard systemic treatment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07552454

• Bimekizumab for palmoplantar pustulosis (PPP)

  This trial tests whether bimekizumab helps adults with palmoplantar pustulosis and is safe compared with a placebo.

  Recruiting at 91 sites Phase 3 UCB Pharma · Birmingham, Alabama and 90 other locations · NCT07219420

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.